MASIMO CORP

Masimo is a global medical technology company that develops and produces monitoring technologies, including measurements, sensors, and patient monitors. The company's solutions are powered by the Masimo Hospital Automation™ and Masimo SafetyNet® platforms, offering connectivity, automation, and telehealth and telemonitoring solutions to improve and automate care delivery in hospitals. Masimo's healthcare business develops, manufactures, and markets noninvasive patient monitoring technologies, hospital automation® and connectivity solutions, and remote monitoring devices. These products and solutions typically include a monitor or circuit board, proprietary single-patient use or reusable sensors, software, and/or cables. Masimo primarily sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, and long-term care facilities. Sales channels include a direct sales force, distributors, and original equipment manufacturer (OEM) partners such as GE Healthcare, Hillrom, Mindray, Philips, Physio-Control, and Zoll. Key measurement technologies include Masimo Signal Extraction Technology® (SET®) pulse oximetry, which is Measure-through Motion and Low Perfusion™ pulse oximetry, and advanced rainbow® Pulse CO-Oximetry parameters like noninvasive hemoglobin (SpHb®). Other modalities include brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions. These technologies are available on devices ranging from bedside hospital monitors like the Root® Patient Monitoring and Connectivity Hub, to handheld and portable devices, and tetherless solutions such as Radius PPG®, Radius VSM®, and the Masimo SafetyNet® remote patient surveillance solution. The Masimo Hospital Automation® Platform facilitates data integration, connectivity, and interoperability through solutions like Patient SafetyNet™, Iris®, iSirona®, Replica®, and UniView®. As of December 28, 2024, the non-healthcare consumer business was part of continuing operations but was being evaluated for divestiture.